Vutrisiran
Oligonucleotide
Overview
Vutrisiran is a oligonucleotide active pharmaceutical ingredient (ChEMBL CHEMBL4594511).
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Vutrisiran expires 28 Jul 2036 and exclusivity 20 Mar 2032. Generic API sourcing typically opens up once these lapse.
Verified Supplier Partner
Do you supply Vutrisiran? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.